Brigimadlin
Brigimadlin (BI 907828) is a potent, orally bioavailable MDM2-p53 antagonist that disrupts the protein-protein interaction to reactivate p53 tumor suppressor function. It has demonstrated antitumor activity in preclinical research models, including studies of metastatic biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), lung adenocarcinoma, and bladder cancer, both in vitro and in vivo.
Product Specifications
CAS Number
2095116-40-6
Product Name Alternative
Brigimadlin, BI 907828, BI907828, BI-907828, p53, MDM2, PSMA 1007, PSMA1007
Field of Research
Cell Biology, Protein Biochemistry
Purity
98.17% (May vary between batches)
Smiles
C (N1[C@@]2 ([C@H] ([C@]3 ([C@@]1 (CC=4N3N=C5C4C=CC (C (O) =O) =C5C) [H]) [H]) C6=C (F) C (Cl) =CC=C6) C=7C (NC2=O) =CC (Cl) =CC7) C8CC8
Molecular Formula
C31H25Cl2FN4O3
Molecular Weight
591.46
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
TAF13 (Transcription Initiation Factor TFIID Subunit 13, Transcription Initiation Factor TFIID 18kD Subunit, TAF (II) 18, TAFII-18, TAFII18, TAF2K, TAFII18) discontinued
TAF13 (Transcription Initiation Factor TFIID Subunit 13, Transcription Initiation Factor TFIID 18kD Subunit, TAF (II) 18, TAFII-18, TAFII18, TAF2K, TAFII18) discontinued